AstraZeneca Faces Suits over Seroquel

AstraZeneca (AZN) launched a public relations push to get doctors to prescribe its best-selling psychiatric drug Seroquel for a string of uses that were not approved by safety regulators, according to a damning internal document released May 20.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.